WATSON DILACOR XR LICENSE: RIGHT Rx FOR HIGH PRESSURE GENERICS MARKET?
Executive Summary
Watson Pharmaceuticals is hoping to build on a successful June by acquiring rights to Rhone-Poulenc Rorer's Dilacor XR for hypertension and angina. The stock closed June 30 up 8% to 42-1/4